Torti Frank's Form 4 filing
Roivant Sciences Ltd. (ROIV) · filed Feb 23, 2026
- Accession no.
- 0001635088-26-000019
- Filed
- Feb 23, 2026
- Trade date
- Feb 19-23, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $82.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Torti FrankCIK 0001647805 | Officer (President and Vant Chair) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | Common Shares | MOption exerciseAcquired | +1,400,000 | $3.85 | +$5,390,000 | 15,136,547 | Direct | |
| Feb 19, 2026 | Common Shares | SSaleDisposed | −1,400,000 | $27.42F1,F2 | −$38,388,000 | 13,736,547 | Direct | |
| Feb 20, 2026 | Common Shares | MOption exerciseAcquired | +1,012,610 | $3.85 | +$3,898,548.5 | 14,749,157 | Direct | |
| Feb 20, 2026 | Common Shares | SSaleDisposed | −1,012,610 | $27.15F1,F3 | −$27,492,361.5 | 13,736,547 | Direct | |
| Feb 23, 2026 | Common Shares | MOption exerciseAcquired | +587,390 | $3.85 | +$2,261,451.5 | 14,323,937 | Direct | |
| Feb 23, 2026 | Common Shares | SSaleDisposed | −587,390 | $27.51F1,F4 | −$16,159,098.9 | 13,736,547 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | Common Shares | MOption exerciseDisposed | −1,400,000 | $0.00 | $0 | 4,626,184 | Direct | |
| Feb 20, 2026 | Common Shares | MOption exerciseDisposed | −1,012,610 | $0.00 | $0 | 3,613,574 | Direct | |
| Feb 23, 2026 | Common Shares | MOption exerciseDisposed | −587,390 | $0.00 | $0 | 3,026,184 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
Referenced by the price of 3 transactions in Table I.
- F2
These Common Shares were sold in multiple transactions at prices ranging from $27.00 to $27.64, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
These Common Shares were sold in multiple transactions at prices ranging from $26.70 to $27.45, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
These Common Shares were sold in multiple transactions at prices ranging from $27.14 to $27.80, inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's shares subject to the trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act entered into by the reporting person on November 20, 2025 which provided for the potential sale of up to 3,000,000 common shares held by the reporting person between February 19, 2026 and June 30, 2026.